Dr. Martens (LON:DOCS) Stock Price Down 0% – What’s Next?

Dr. Martens plc (LON:DOCS)’s stock price was down 0% on Tuesday . The stock traded as low as GBX 61.70 and last traded at GBX 62.69. Approximately 959,172 shares changed hands during trading, a decline of 93% from the average daily volume of 13,322,682 shares. The stock had previously closed at GBX 62.70.

Wall Street Analysts Forecast Growth

DOCS has been the topic of a number of research analyst reports. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Dr. Martens in a report on Tuesday, February 3rd. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a report on Tuesday, January 27th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Stock Performance

The stock has a market capitalization of £617.71 million, a P/E ratio of 37.59, a PEG ratio of 6.40 and a beta of 0.20. The firm has a 50-day moving average of GBX 66.50 and a 200 day moving average of GBX 77.68. The company has a quick ratio of 1.13, a current ratio of 2.18 and a debt-to-equity ratio of 120.66.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.